YLYizhi Li

Yizhi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yizhi Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Aoran Liu

    The First Laboratory of Cancer Institute, the First Hospital of China Medical University, Shenyang, China

    1 shared publication
  • Lirong Yan

    The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China

    1 shared publication
  • Qian Xu

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    1 shared publication
  • Songyi Liu

    Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, China

    1 shared publication
  • Yuan Yuan

    Tumor Etiology and Screening Department of Cancer Institute, and Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, the First Hospital of China Medical University, Shenyang, China

    1 shared publication

Latest Publications

  • Open Access

    Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression

    by Yizhi Li, Aoran Liu, Songyi Liu, Lirong Yan, Yuan Yuan, Qian Xu

    The expression of CXC motif chemokine 17 (CXCL17) and its reported membrane receptor G-protein-coupled receptor 35 (GPR35) in different gastric pathological lesions and their clinical implications are largely unknown. In this study, a total of 860 pathological sections were immune-stained with either anti-CXCL17 or anti-GPR35 antibodies. Their expression was scored within the area of the normal gastric gland of non-atrophic gastritis (NAG-NOR), intestinal metaplasia of atrophic gastritis (AG-IM), IM adjacent to GC (GC-IM), and GC tissue. The clinical significance and potential function of CXCL17 and GPR35 were explored using multiple methods. Our results suggested that CXCL17 expression was gradually upregulated during the pathological progress of gastric diseases (NAG-NOR < AG-IM < GC-IM), but significantly downregulated when GC occurred. GPR35 had a similar expression pattern but its expression in GC remained abundant. High CXCL17 expression in GC was associated with less malignant behavior and was an independent biomarker of favorable prognosis. Overexpressing CXCL17 in HGC27 cells significantly upregulated CCL20 expression. TCGA analysis identified that CXCL17 was negatively correlated with some cancer-promoting pathways and involved in inflammatory activities. CTRP analysis revealed that gastric cell lines expressing less CXCL17 and were more sensitive to the CXCR2 inhibitor SB-225002.